Sulopenem

Last updated
Sulopenem
Sulopenem.svg
Clinical data
ATC code
  • None
Identifiers
  • (5R,6S)-6-[(1R)-1-Hydroxyethyl]-7-oxo-3-[(1R,3S)-1-oxothiolan-3-yl]sulfanyl-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
Formula C12H15NO5S3
Molar mass 349.43 g·mol−1
3D model (JSmol)
  • C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)S[C@H]3CC[S@@](=O)C3)C(=O)O)O
  • InChI=1S/C12H15NO5S3/c1-5(14)7-9(15)13-8(11(16)17)12(20-10(7)13)19-6-2-3-21(18)4-6/h5-7,10,14H,2-4H2,1H3,(H,16,17)/t5-,6+,7+,10-,21-/m1/s1
  • Key:FLSUCZWOEMTFAQ-PRBGKLEPSA-N

Sulopenem (CP-70,429) is a thiopenem antibiotic derivative from the penem family, which unlike most related drugs is orally active. It was developed in Japan in the 1990s, and has been approved to treat uncomplicated urinary tract infections in combination with probenecid (brand name Orlynvah). It has reached Phase III clinical trials on several occasions and continues to be the subject of ongoing research into potential applications, especially in the treatment of multiple drug resistant urinary tract infections. [1] [2] [3] [4] [5]

In October 2024, the US Food and Drug Administration approved sulopenem etzadroxil with probenecid combination for the treatment of urinary tract infections caused by Escherichia coli , Klebsiella pneumoniae , or Proteus mirabilis in adult women with limited alternative oral antibiotic options. [6]

See also

References

  1. ↑ Minamimura M, Taniyama Y, Inoue E, Mitsuhashi S (July 1993). "In vitro antibacterial activity and beta-lactamase stability of CP-70,429 a new penem antibiotic". Antimicrobial Agents and Chemotherapy. 37 (7): 1547–1551. doi:10.1128/AAC.37.7.1547. PMC   188011 . PMID   8363389.
  2. ↑ Hamilton-Miller JM (November 2003). "Chemical and microbiologic aspects of penems, a distinct class of beta-lactams: focus on faropenem". Pharmacotherapy. 23 (11): 1497–1507. doi:10.1592/phco.23.14.1497.31937. PMID   14620395. S2CID   43705118.
  3. ↑ Ednie LM, Appelbaum PC (May 2009). "Antianaerobic activity of sulopenem compared to six other agents". Antimicrobial Agents and Chemotherapy. 53 (5): 2163–2170. doi:10.1128/AAC.01557-08. PMC   2681565 . PMID   19223615.
  4. ↑ Bader MS, Loeb M, Leto D, Brooks AA (April 2020). "Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents". Postgraduate Medicine. 132 (3): 234–250. doi:10.1080/00325481.2019.1680052. PMID   31608743. S2CID   204545734.
  5. ↑ Veeraraghavan B, Bakthavatchalam YD, Sahni RD (December 2021). "Oral Antibiotics in Clinical Development for Community-Acquired Urinary Tract Infections". Infectious Diseases and Therapy. 10 (4): 1815–1835. doi:10.1007/s40121-021-00509-4. PMC   8572892 . PMID   34357517.
  6. ↑ "Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections". Iterum Therapeutics plc. 2024-10-25. Retrieved 2024-10-25.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.